Cathay Biotech (688065)2025-02-27 10:00Financial Performance - In 2024, the company achieved operating revenue of CNY 295,648.59 million, a year-on-year increase of 39.84%[4] - The total profit for 2024 was CNY 54,573.76 million, reflecting a year-on-year growth of 21.57%[4] - The net profit attributable to shareholders was CNY 48,673.00 million, up 32.80% compared to the previous year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 50.87% to CNY 46,249.85 million[4] - Basic earnings per share rose to CNY 0.84, representing a 33.33% increase year-on-year[4] - The weighted average return on equity was 4.33%, an increase of 1.02 percentage points from the previous year[4] Assets and Equity - Total assets at the end of 2024 were CNY 1,901,648.11 million, a 0.97% increase from the beginning of the year[4] - The equity attributable to shareholders reached CNY 1,150,470.11 million, up 3.05% from the start of the year[4] Market Expansion and R&D - The company successfully expanded into the long-chain dicarboxylic acid market, significantly increasing sales volume and revenue[5] - The company continued to invest in R&D for bio-based new materials, achieving progress in cooperation with leading enterprises in downstream sectors[4]